North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-03-04-02 Anti-androgens

Abiraterone
Formulary
  • Approved for castration-resistant metastatic prostate cancer in line with NICE.
  • Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy.
Link  NICE TA259: Abiraterone for castration resistant prostate cancer
Link  NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Red View adult BNF  View SPC online  View childrens BNF  HCD
Apalutamide  Erleada®
Formulary
  • 60mg tablets
  • Approved for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults in line with NICE
  • Approved for treating hormone-sensitive metastatic prostate cancer in adults in line with NICE, only if:
    • docetaxel is not suitable

 

Link  NICE TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
Link  NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

Red View adult BNF  View SPC online  View childrens BNF
Bicalutamide
Formulary

Initiate with specialist advice.


Green plus View adult BNF  View SPC online  View childrens BNF
Cyproterone
Formulary

Green plus View adult BNF  View SPC online  View childrens BNF
Darolutamide Nubeqa®
Formulary
  • 300mg tablets
  • Approved for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease in line with NICE
  • Approved with andorgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer in line with NICE and NHSE Specialised Commissioning guidance

 

Link  NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Link  NICE TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer

Red View adult BNF  View SPC online  View childrens BNF  HCD
Enzalutamide
Formulary
  • Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
  • Approved for treating hormone-sensitive metastatic prostate cancer in line with NICE
Link  NICE TA316: Enzalutamide for prostate cancer
Link  NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Link  NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer

Red View adult BNF  View SPC online  View childrens BNF
Flutamide
Formulary

Green plus View adult BNF  View SPC online  View childrens BNF